Sangamo Therapeutics (NASDAQ: SGMO) files 8-K amendment adding Eli Lilly and Astellas agreements
Rhea-AI Filing Summary
Sangamo Therapeutics, Inc. filed Amendment No. 1 to a previously submitted current report to add two asset purchase agreements as exhibits. The amendment does not change any information previously disclosed in the original report covering Items 1.01, 1.03, 2.03 and 2.05.
The new exhibits are asset purchase agreements dated June 22, 2026, with counterparties including Eli Lilly and Company and Astellas Gene Therapies, Inc., along with certain Sangamo subsidiaries. The filing is administrative in nature and focused on completing the exhibit set.
Positive
- None.
Negative
- None.
8-K Event Classification
5 items: 1.01, 1.03, 2.03, 2.05, 9.01
5 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.03
Bankruptcy or Receivership
Business
The company or a significant subsidiary has filed for bankruptcy or entered receivership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 2.05
Costs Associated with Exit or Disposal Activities
Financial
The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Amendment No. 1, Asset Purchase Agreement, emerging growth company, Current report
4 terms
Amendment No. 1 regulatory
"Sangamo Therapeutics, Inc. is filing this Amendment No. 1 to its"
Asset Purchase Agreement financial
"Asset Purchase Agreement, dated June 22, 2026, by and among"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Current report regulatory
"Interested parties should refer to the Original 8-K for Items 1.01, 1.03, 2.03 and 2.05."
A current report is a regulatory filing companies must submit quickly when a significant event—like a leadership change, major contract, financial restatement, or legal development—occurs. It gives investors an official, timely snapshot of news that could change a company’s outlook, similar to a breaking-news alert for a business; traders use it to reassess value and risk right away.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Sangamo Therapeutics’ 8-K amendment filed on June 18, 2026 do?
The amendment adds two asset purchase agreements as exhibits to a prior current report. It does not alter any information previously disclosed in Items 1.01, 1.03, 2.03 or 2.05 of the original report.
Does Sangamo’s 8-K/A change the substance of the earlier SGMO 8-K?
No, the amendment explicitly states it does not amend or change any information in the original report. It is filed solely to include exhibits 2.1 and 2.2 that were not previously attached.
Which agreements are attached in Sangamo Therapeutics’ latest 8-K amendment?
The amendment files two asset purchase agreements dated June 22, 2026. One is among Sangamo entities and Eli Lilly and Company, and the other is between Sangamo Therapeutics, Inc. and Astellas Gene Therapies, Inc.
Who are the counterparties to Sangamo’s new asset purchase agreements?
Counterparties include Eli Lilly and Company and Astellas Gene Therapies, Inc., along with Sangamo Therapeutics, Inc. and certain Sangamo subsidiaries in the United Kingdom, France, and Ceregene, Inc., as listed in the exhibit descriptions.
Where can investors find the detailed terms of Sangamo’s asset purchase agreements?
The detailed terms are contained in exhibits 2.1 and 2.2 referenced in the amendment. Investors should review those exhibits together with the original current report for a complete picture of the transactions.